Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries

International Clinical Psychopharmacology

Volumn 21, Issue 6, 2006, Pages 355-362

  Barbui, Corrado ^a   Nosè, Michela ^a   Mazzi, Maria Angela ^a   Thornicroft, Graham ^b   Schene, Aart ^c   Becker, Thomas ^d,e   Bindman, Jonathan ^a   Leese, Morven ^b   Helm, Hedda ^d   Koeter, Maarten ^c   Weinmann, Stefan ^e   Tansella, Michele ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Antipsychotic drugs; Dose regimens; Polypharmacy; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GERMANY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIVARIATE ANALYSIS; NETHERLANDS; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; FOLLOW-UP STUDIES; GERMANY; GREAT BRITAIN; HUMANS; ITALY; MALE; MIDDLE AGED; NETHERLANDS; POLYPHARMACY; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIOECONOMIC FACTORS; TIME;

EID: 33749326014     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000224785.68040.43     Document Type: Article

References (25)

1. Ananth J (2005). Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia. Evidence Based Mental Health 8:55.
2. Barbui C, Ciuna A, Nose M, Levi D, Andretta M, Patten SB, et al. (2005a). Drug treatment modalities in psychiatric inpatient practice. A 20-year comparison. Eur Arch Psychiatry Clin Neurosci 255:136-142.
3. Barbui C, Nose M, Bindman J, Schene A, Becker T, Mazzi MA, et al. (2005b). Gender differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol 25:521-526.
4. Becker T, Hulsmann S, Knudsen HC, Martiny K, Amaddeo F, Herran A, et al. (2002). Provision of services for people with schizophrenia in five European regions. Soc Psychiatry Psychiatr Epidemiol 37:465-474.
5. Biancosino B, Barbui C, Marmai L, Dona S, Grassi L (2005). Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 20:305-309.
6. Centorrino F, Eakin M, Bahk WM, Kelleher JP, Goren J, Salvatore P, et al. (2002). Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 159:1932-1935.
7. Centorrino F, Fogarty KV, Sani G, Salvatore P, Cincotta SL, Hennen J, et al. (2005). Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum Psychopharmacol 20:485-492.
8. Dingemans PM, Linszen DH, Lenior ME, Smeets RM (1995). Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Psychopharmacology (Berlin) 122:263-267.
9. Freudenreich O, Goff DC (2002). Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106:323-330.
10. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004). Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65:1377-1388.
11. Grohmann R, Engel RR, Geissler KH, Ruther E (2004). Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37(Suppl 1):S27-S38.
12. Jaffe AB, Levine J (2003). Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Safety 12:41-48.
13. Janssen B, Weinmann S, Berger M, Gaebel W (2004). Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 30:1023-1033.
14. Lehmann P (2005). All about PSY DREAM. Psychiatric drug registration, evaluation & all-inclusive monitoring. Epidemiol Psychiatr Soc 14:15-21.
15. Magliano L, Fiorillo A, Guarneri M, Marasco C, Malangone C, Maj M (2004). Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey. Eur J Clin Pharmacol 60:513-522.
16. Procyshyn RM, Kennedy NB, Tse G, Thompson B (2001). Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 46:334-339.
17. Rijcken CA, Monster TB, Brouwers JR, de Jong-van den Berg LT (2003). Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacol 2003:657-659.
18. Ruggeri M, Koeter M, Schene A, Bonetto C, Vazquez-Barquero JL, Becker T, et al. (2005). Factor solution of the BPRS-expanded version in schizophrenic outpatients living in five European countries. Schizophr Res 75:107-117.
19. Sernyak MJ, Rosenheck R (2004). Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 65:1597-1600.
20. Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS, et al. (2004). Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58:178-183.
21. Suzuki T, Uchida H, Tanaka KF, Nomura K, Takano H, Tanabe A, et al. (2004). Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 7:133-142.
22. Tomasi R, de Girolamo G, Santone G, Picardi A, Micciolo R, Semisa D, Fava S (2005). Drug prescription in Italian residential facilities. Epidemiol Psychiatr Soc 14:77-90.
23. Waddington JL, Youssef HA, Kinsella A (1998). Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173:325-329.
24. WHO Collaborating Centre for Drug Statistic Methodology (2003). Guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for drug statistic methodology edn. Oslo: WHO.
25. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. (1990). SCAN. Schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry 47:589-593.